October 1, 2009
By:Jill Wechsler
Stiffer enforcement of quality standards aims to restore public confidence in agency actions.
 |
September 1, 2009
By:Jill Wechsler
The FDA is encouraging manufacturers to invest in research and development for new vaccines and therapeutics to combat third-world diseases.
|
August 1, 2009
By:Jill Wechsler
Pressures to reduce healthcare spending generates proposals to spur competition, cut costs.
|
July 1, 2009
By:Jill Wechsler
The FDA seeks new strategies for improving the safe use of opioids and other high-risk medicines, including erythropoiesis stimulating agents.
|
June 1, 2009
By:Jill Wechsler
Agency officials promise swift action against violators of drug safety and quality regulations.
|
May 1, 2009
By:Jill Wechsler
Authorities are pushing for CE; manufacturers prefer to focus on value.
|
April 1, 2009
By:Jill Wechsler
The FDA is poised to gain more authority and resources to ensure product quality.
|
March 1, 2009
By:Jill Wechsler
Broader transparency in product prices and payments to researchers aim to curb conflicts of interest and rationalize drug expenditures.
|
February 1, 2009
By:Jill Wechsler
With cuts in healthcare, biotech drugs are under scrutiny.
|
| 
